Switch theme
Sign up to access all valuation multiples
Inventurus Knowledge Solutions Ltd is a technology-enabled healthcare solutions provider and offer a care enablement platform assisting physician enterprises in the USA, Canada and Australia, with a focus on the USAÂ markets. It is partner for outpatient and inpatient care organizations, enabling healthcare organizations deliver superior clinical care, improve population health outcomes, and transition to the fee for value model while optimizing their revenue and reducing operating costs, It has nearly 778 healthcare organizations as clients, including health systems, academic medical centers, multi-specialty medical groups, single specialty medical groups, ancillary healthcare organizations and other outpatient and inpatient healthcare delivery organization.
2006
13.5K+
LTM Revenue $321M
LTM EBITDA $94.1M
$3.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
IKS Health has a last 12-month revenue (LTM) of $321M and a last 12-month EBITDA of $94.1M.
In the most recent fiscal year, IKS Health achieved revenue of $312M and an EBITDA of $94.7M.
IKS Health expects next 12-month revenue of XXX and NTM EBITDA of XXX
See IKS Health valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $321M | XXX | $312M | XXX | XXX | XXX |
| Gross Profit | $232M | XXX | $312M | XXX | XXX | XXX |
| Gross Margin | 72% | XXX | 100% | XXX | XXX | XXX |
| EBITDA | $94.1M | XXX | $94.7M | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 30% | XXX | XXX | XXX |
| EBIT | $80.7M | XXX | $76.9M | XXX | XXX | XXX |
| EBIT Margin | 25% | XXX | 25% | XXX | XXX | XXX |
| Net Profit | $60.1M | XXX | $56.9M | XXX | XXX | XXX |
| Net Margin | 19% | XXX | 18% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $67.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, IKS Health's stock price is INR 1506 (or $18).
IKS Health has current market cap of INR 252B (or $2.9B), and EV of INR 258B (or $3.0B).
See IKS Health trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.0B | $2.9B | XXX | XXX | XXX | XXX | $0.36 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, IKS Health has market cap of $2.9B and EV of $3.0B.
IKS Health's trades at 10.5x EV/Revenue multiple, and 34.6x EV/EBITDA.
Equity research analysts estimate IKS Health's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
IKS Health has a P/E ratio of 49.1x.
See valuation multiples for IKS Health and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.9B | XXX | $2.9B | XXX | XXX | XXX |
| EV (current) | $3.0B | XXX | $3.0B | XXX | XXX | XXX |
| EV/Revenue | 9.4x | XXX | 10.5x | XXX | XXX | XXX |
| EV/EBITDA | 32.1x | XXX | 34.6x | XXX | XXX | XXX |
| EV/EBIT | 37.4x | XXX | 42.3x | XXX | XXX | XXX |
| EV/Gross Profit | 13.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 49.1x | XXX | 55.0x | XXX | XXX | XXX |
| EV/FCF | 77.7x | XXX | 102.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialIKS Health's last 12 month revenue growth is 18%
IKS Health's revenue per employee in the last FY averaged $23K, while opex per employee averaged $17K for the same period.
IKS Health's rule of 40 is 49% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
IKS Health's rule of X is 75% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for IKS Health and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 30% | XXX | XXX | XXX |
| EBITDA Growth | 27% | XXX | 24% | XXX | XXX | XXX |
| Rule of 40 | 49% | XXX | 49% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 75% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $23K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $17K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 75% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Athens Medical Centre | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
IKS Health acquired XXX companies to date.
Last acquisition by IKS Health was XXXXXXXX, XXXXX XXXXX XXXXXX . IKS Health acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was IKS Health founded? | IKS Health was founded in 2006. |
| Where is IKS Health headquartered? | IKS Health is headquartered in India. |
| How many employees does IKS Health have? | As of today, IKS Health has 13.5K+ employees. |
| Is IKS Health publicy listed? | Yes, IKS Health is a public company listed on NSE. |
| What is the stock symbol of IKS Health? | IKS Health trades under IKS ticker. |
| When did IKS Health go public? | IKS Health went public in 2024. |
| Who are competitors of IKS Health? | Similar companies to IKS Health include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Ramsay Health. |
| What is the current market cap of IKS Health? | IKS Health's current market cap is $2.9B |
| What is the current revenue of IKS Health? | IKS Health's last 12 months revenue is $321M. |
| What is the current revenue growth of IKS Health? | IKS Health revenue growth (NTM/LTM) is 18%. |
| What is the current EV/Revenue multiple of IKS Health? | Current revenue multiple of IKS Health is 9.4x. |
| Is IKS Health profitable? | Yes, IKS Health is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of IKS Health? | IKS Health's last 12 months EBITDA is $94.1M. |
| What is IKS Health's EBITDA margin? | IKS Health's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of IKS Health? | Current EBITDA multiple of IKS Health is 32.1x. |
| What is the current FCF of IKS Health? | IKS Health's last 12 months FCF is $38.9M. |
| What is IKS Health's FCF margin? | IKS Health's last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of IKS Health? | Current FCF multiple of IKS Health is 77.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
